PremiumRatingsOptimistic Buy Rating for Atossa Therapeutics Driven by Strategic Focus on Z-endoxifen and Strong Financial Position Biotech Alert: Searches spiking for these stocks today Atossa Therapeutics announces issuance of U.S. patent for (Z)-endoxifen PremiumRatingsStrategic Advancements and Promising Clinical Data Drive Buy Rating for Atossa Therapeutics Atossa Therapeutics Reports 2024 Financial Results and Updates Atossa Therapeutics reports Q4 EPS (20c), consensus (22c) PremiumRatingsPositive Buy Rating for Atossa Therapeutics Driven by Promising Z-endoxifen Efficacy in Breast Cancer Atossa Therapeutics to pursue metastatic breast cancer for (Z)-endoxifen Atossa Therapeutics issues statement in response to PTAB ruling 
